0.045
0.00 (-8.48%)
| Penutupan Terdahulu | 0.050 |
| Buka | 0.045 |
| Jumlah Dagangan | 141 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -8,995.34% |
| EPS Cair (TTM) | -6.58 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -24.40% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 47.32% |
| Nisbah Semasa (MRQ) | 2.80 |
| Aliran Tunai Operasi (OCF TTM) | -5.08 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -3.84 M |
| Pulangan Atas Aset (ROA TTM) | -127.69% |
| Pulangan Atas Ekuiti (ROE TTM) | -745.47% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Health Information Services (US) | Menurun | Bercampur |
| Health Information Services (Global) | Menurun | Bercampur | |
| Stok | Aclarion Inc | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | -2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | NA |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 0.0 |
| Purata | -0.67 |
|
Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. The company develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in Broomfield, Colorado. |
|
| Sektor | Healthcare |
| Industri | Health Information Services |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |